ESR1 and breast cancer: Thus, immunohistochemical Ki67 assay, together with ER, PgR and HER2 status, was chosen as a useful and easily-to-apply surrogate for gene expression profile to defined breast cancer molecular subtypes, despite a lesser analytical validity than molecular testing and a reliable clinical validation.